How to avoid China's Sinovac vaccine?

[Thick Face Black Heart]

Sinovac's efficacy is only 51% and yet MoH is approving it.

View attachment 112702

MOH is not approving Sinovac.

They are merely creating a politically convenient bureaucratic structure to allow private companies to import and use it, and hence, make Singapore appear "good" in the eyes of China. The reality is that PAP is terrified of China and needs to please China.

Don;t worry, no one is going to be injected with SInovac against his or her will.

 

[knowwhatyouwantinlife]

Mrna tech is like training your immune system to recognise things much like what we term muscle memory in the arm forces...take for example everytime u see a shadow in the dark you are program to chant a mantra and heavenly beings will come and remove the shadow, however u r programmed to chant regardless of who the shadow is (could be your family member),z attenuated tech tells you to recognise that there is a shadow but whether you want to chant take a gun to shoot etc it up to the cells to make their own decision hence the lower efficacy rate...me rather have a tech that transforms the shadow into 2 babes for me to have a good time...vaccinate or not and with what vaccine choice is entirely yours...

 

[redbull313]

so glad I left shittypore

 

[LITTLEREDDOT]

Hundreds of Indonesian healthcare workers contract Covid-19 despite vaccination, dozens hospitalised​

Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.PHOTO: EPA-EFE

JUN 17, 2021


JAKARTA (REUTERS) - More than 350 Indonesian doctors and healthcare workers have contracted Covid-19 despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.
Most of the doctors were asymptomatic and self-isolating at home, said Dr Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.
Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90 per cent in the district.
Designated as a priority group, Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.
Almost all have received the Covid-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association (IDI).
While the number of Indonesian healthcare workers dying from Covid-19 has decreased significantly - dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCovid-19 - public health experts say the Java hospitalisations are a cause for concern.

"The data shows they have the Delta variant (in Kudus) so it is no surprise that the breakthrough infection is higher than before because, as we know, the majority of healthcare workers in Indonesia got Sinovac and we still don't know yet how effective it is in the real world against the Delta variant," said Dr Dicky Budiman, an epidemiologist from Australia's Griffith University.
Spokesmen from Sinovac and Indonesia's ministry of health were not immediately available for comment on the efficacy of Sinovac's CoronaVac against newer coronavirus variants.
Grappling with one of the worst outbreaks in Asia, with more than 1.9 million cases and 53,000 deaths, there has been a heavy toll on Indonesia's doctors and nurses, with 946 deaths.
Many are now experiencing pandemic fatigue and taking an increasingly laissez-faire approach to health protocols after being vaccinated, said Ms Lenny Ekawati, from LaporCovid-19.

"That phenomenon happens quite often these days, not only within the community but also healthcare workers," she said. "They think because they are vaccinated that they are safe."
But as more cases of the highly transmissible Delta variant are identified in the world's fourth-most populous nation, the data is starting to tell a different story.
Across Indonesia, at least five doctors and one nurse have died from Covid-19 despite being vaccinated, according to the data initiative group, although one had received only their first shot.
In Kudus, one senior doctor has died, said IDI, although it is understood he had a comorbidity.
In the Indonesian capital Jakarta, radiologist Prijo Sidipratomo told Reuters he knew of at least half a dozen doctors in the city who had been hospitalised with Covid-19 in the past month despite being vaccinated, with one currently being treated in ICU.
"It is alarming for us because we cannot rely on vaccinations only," he said, urging people to strictly adhere to health protocols.
Weeks after the Muslim Eid Al-Fitr holidays, Indonesia has experienced a surge in cases, with the positivity rate exceeding 23 per cent on Wednesday (June 16) and daily cases nearing 10,000, the highest since late February.
In its latest situation report, the World Health Organisation called for Indonesia to implement a stricter lockdown with increased transmission due to variants of concern and a "drastic increase in bed occupancy rates" necessitating urgent action.

 

[LITTLEREDDOT]

How would you know whether the person next to you is vaccinated but with Sinovac vaccine or with Pfizer/Moderna?

Evidence from overseas shows Sinovac vaccine carries some risk of Covid-19 infection despite jabs​

The Sinovac vaccine has shown variable protection across multiple studies carried out internationally.ST PHOTO: LIM YAOHUI

Clara Chong

Jun 18, 2021

SINGAPORE - The Sinovac vaccine carries some risk of a person being infected despite taking the jabs, based on evidence from other countries, Singapore's director of medical services Kenneth Mak said on Friday (June 18).
For instance, there has been a recent report of healthcare workers in Indonesia still being infected even after receiving the Sinovac vaccine, and in other countries, the authorities are starting to think about booster vaccinations just six months out from an original vaccination, Associate Professor Mak added.
"So it does give the impression that the efficacy of different vaccines will vary quite significantly," he said.
Prof Mak, speaking at a virtual Covid-19 multi-ministry task force press conference, noted that the Pfizer-BioNTech and Moderna vaccines Singapore is using are among those with the highest efficacy.
It was previously reported that the Pfizer-BioNTech and Moderna mRNA vaccines have consistently shown to be highly efficacious, with an efficacy rate of around 90 per cent.
The Sinovac vaccine has shown variable protection across multiple studies carried out internationally, with the most complete analysis showing a vaccine efficacy of 51 per cent.



Prof Mak said Singapore's Health Sciences Authority (HSA) has yet to approve Sinovac as there is still some critical data that the manufacturer has not provided to give the authorities the complete assurance about the quality and safety profile of the vaccine.
He added: "And because that data is still limited, HSA has not been able to make progress in converting Sinovac from simply a vaccine made available through the special access route into one that actually has that pandemic special access route (PSAR) approval."
Demand for the Pfizer and Moderna jabs - the two HSA-approved vaccines in Singapore - is also high, with many people waiting to book their appointments.
"But we are releasing the booking slots based on supplies," Health Minister Ong Ye Kung said, assuring that there will be sufficient supplies for the whole population to receive full protection.
"The question is really one of timing... whether we can work with the suppliers to see whether some of those (vaccines) can come earlier. And then we are in a better position to be able to open," he added.
Prof Mak said the two vaccines arrive in Singapore in batches on their own time, so supplies for each vaccine will vary at different times.
He added: "These vaccines are all HSA PSAR-approved. They're fine for our use, and it's okay to register for the Moderna vaccine... you don't have to wait for the Pfizer-BioNTech vaccine."

 

[jw5]

from msn.com:

Singapore sees first day rush for Sinovac vaccine​

SINGAPORE (Reuters) - Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time on Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite already available rival vaccines having far higher efficacy.

Singapore has vaccinated almost half its 5.7 million population with at least one dose of the vaccines from Pfizer-BioNTech and Moderna.


Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with Sinovac's 51%.

Earlier this week, officials in neighbouring Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants.

A number of the people rushing for the Sinovac shot on the first day of its availability in Singapore were Chinese nationals, who felt it would make it easier to travel home without going through quarantine.

Singapore allowed the usage of the Sinovac vaccine by private healthcare institutions under a special access route, following an emergency use approval by the World Health Organization (WHO) earlier this month.

Ong Ye Kung, Singapore's health minister, said on Friday the government is still awaiting critical data from Sinovac before including it in the national vaccination programme.

Meantime, authorities have selected 24 private clinics to administer its current stock of 200,000 doses. The clinics are charging between S$10-25 ($7.5-$18.6 ) per dose.

Serena Wee, CEO of Icon Cancer Centre, said about 1,000 people have registered so far, exceeding its initial stock of 200 doses.

Wee Healthfirst, another approved clinic, put a notice at its entrance on Friday, saying it had stopped reservations for the vaccine until next Thursday, citing "overwhelming demand". A receptionist said about 1,000 people had registered there.

Leong Hoe Nam, an infectious diseases doctor at Rophi Clinic, also said he had been "overwhelmed" by people wanting the Sinovac shot.

Tang Guang Yu, a 49-year-old engineer, was among the Chinese nationals resident in Singapore who waited for the Sinovac shot rather than take a foreign-made vaccine that he thought might not be recognised by authorities back home.

"No one wants to be quarantined for a month, I don't have so many days of leave," Tang told Reuters as he queued outside a clinic.

Travellers to China may have to be quarantined at a facility and at home for up to a month depending on their destination city, regardless of vaccination status, according to the Chinese government website.

Other people said they have more confidence in the Sinovac vaccine since it is based on conventional technology, while those developed by Pfizer/BioNTech and Moderna use a newly developed messenger RNA platform.

"The mRNA technology has been around for 30 years, but it has never been injected into human until recently due to COVID-19 emergency, how safe it is?" asked Singaporean Chua Kwang Hwee, 62, as he lined up outside a clinic to enquire about getting the Sinovac shot.

Singapore's health ministry says persons with a history of allergic reaction or anaphylaxis to mRNA COVID-19 vaccine or its components as well as severely immunocompromised individuals should not receive the mRNA-based vaccines.

Sinovac vaccine uses an inactivated or killed virus that cannot replicate in human cells to trigger an immune response.

In recent weeks, several social media messages have popped up saying inactivated virus COVID-19 vaccines, like Sinovac's, provide superior protection against variants than mRNA vaccines. Other messages on platforms have said the mRNA vaccines are less safe.

Authorities have rejected these claims, saying they are safe and highly effective.

($1 = 1.3412 Singapore dollars)

 

[jw5]

from msn.com

'Significant' problems linked to Sinovac vaccine in other countries: MOH official​

SINGAPORE — There is a significant risk of "vaccine breakthrough" with the Sinovac vaccine, or CoronaVac, with international evidence showing that many who had taken it were later infected with COVID-19, said the Ministry of Health's (MOH) director of medical services Kenneth Mak on Friday (18 June).

Addressing reporters at a virtual media briefing by the multi-ministry taskforce on the coronavirus, Associate Professor Kenneth Mak said that Singapore has been assessing the experience of countries such as Indonesia, which has vaccinated a "larger proportion" of the population using CoronaVac.


Alluding to recent reports that more than 350 doctors and medical workers in Indonesia caught COVID in Indonesia despite being vaccinated with CoronaVac, Associate Professor Mak noted, "It's not a problem associated with Pfizer. This is actually a problem associated with the Sinovac vaccine, and in other countries, they are now starting to think about booster vaccinations, even six months out from an original vaccination for some of these vaccines as well.

"So it does give the impression that the efficacy of different vaccines will vary quite significantly," said Prof Mak, stressing that Singapore has "great confidence" in the Pfizer-BioNTech and Moderna vaccines, of which more than 4.7 million doses have so far been administered in the country.

Prof Mak was responding to a question on whether Singapore intends to introduce the Sinovac vaccine into its national vaccination programme. On Wednesday, 24 healthcare institutions were licensed by the Ministry of Health (MOH) to provide the Sinovac vaccine to those who wish to take it.

The 24 institutions were selected under the Private Hospitals and Medical Clinics Act (PHMCA) to be licensed providers under the Special Access Route (SAR). A number of the approved institutions have been seeing long queues of individuals forming at their premises, with some saying their telephones lines have been ringing non-stop in recent days, according to local media reports.

Sinovac remains unregistered and is not authorised by the Health Sciences Authority (HSA), and is to be provided only under the SAR framework. As such, it will not be covered under the Vaccine Injury Financial Assistance Programme (VIFAP) meant for the national vaccination programme.

Prof Mak noted that there still is some "outstanding data" on the vaccine that Sinovac has not provided to HSA, which is required to give "complete assurance" about its quality and safety profile. "We look forward, if data becomes available for us, then to (commence) this process of evaluation but unfortunately we're not able to do so."

 

[laksaboy]

China can't produce a proper baby milk powder but you definitely can trust its vaccines.

I hope those 24 lucky clinics start lawyering up now.

 

[sghainanlee]

Brain wash by chao angmoh again. Always say Western are the best, then bad mouthing Chinese and China is safer.

Vaccine is English shit who knows what it means by the word vaccine.

Chinese is antidote 消毒药. Angmoh say Chinese one is 70% good then be it.

Ur narrative is sway to Western value and u are a snake oil salesman for the West here... 卖花说花香 only.

Dickhead.

go fark a gay spider nao...

 

[jw5]

from msn.com:

COVID-19: Sinovac recipients need to undergo pre-event testing​

SINGAPORE — Recipients of the Sinovac COVID-19 vaccine will still have to undergo pre-event testing, said the Ministry of Health (MOH) on Wednesday (30 June).

This is because the Chinese-made vaccine, also known as CoronaVac, is not part of the national vaccination programme, which only includes vaccines with sufficient data on their protection against the virus.

To date, only the Pfizer-BioNTech and Moderna messenger RNA (mRNA) vaccines have been approved for use in Singapore's national vaccination drive.

Vaccines imported under the special access route will not be subsidised, and those taking them will also not be eligible for the vaccine injury financial assistance programme for COVID-19 vaccination.

"Doctors are required to inform their patients receiving vaccines under the Special Access Route (SAR) that they may not be regarded in the same manner as those vaccinated under our national programme, so that their patients can weigh the risk versus benefits of proceeding with vaccination using such SAR vaccines," said MOH in reply to media queries on Wednesday.

"COVID-19 vaccines that are not part of our national vaccination programme may not have documented sufficient data on their protection against COVID-19 infection, especially against the Delta variant that is currently circulating," the ministry added.

The authorities earlier this month announced that the Sinovac vaccine can be administered under the special access route for private healthcare providers, a day after it was approved for emergency use by the World Health Organisation.

Singapore received 200,000 doses of the vaccine with a shelf life of two years earlier this year, having signed advanced purchase agreements with its manufacturer late last year. However, it was not approved for use pending further data from the manufacturer.

Two weeks ago, MOH announced that 24 private healthcare providers had been licensed to provide the Sinovac vaccine, which the ministry released to them at no cost. Recipients will need to pay between $10 and $25 per dose, including a consultation fee and 7 per cent GST.

Speaking at a multi-ministry taskforce press conference on 18 June, MOH's director of medical services Kenneth Mak also warned of a significant risk of "vaccine breakthrough"with the Sinovac vaccine, with international evidence showing that many who had taken it were later infected with COVID-19.

"It's not a problem associated with Pfizer. This is actually a problem associated with the Sinovac vaccine, and in other countries, they are now starting to think about booster vaccinations, even six months out from an original vaccination for some of these vaccines as well. So it does give the impression that the efficacy of different vaccines will vary quite significantly," he said.

Noting that outstanding data has yet to be provided to the Health Sciences Authority, he added, "We look forward, if data becomes available for us, then to (commence) this process of evaluation but unfortunately we're not able to do so."

Despite the Sinovac vaccine not given regulatory approval, it has attracted strong demand among a number of people who had formed queues outside the private clinics offering it in recent days. According to media reports, some prefer the technology behind Sinovac, which uses an inactivated virus, unlike other mRNA vaccines.

 

[tanwahtiu]

go fark a gay spider nao...

Go fuck yourself.